Reyedar

About Reyedar

The startup manufactures medical devices that utilize eye tracking and artificial intelligence to expedite the diagnostic process for glaucoma and neurodegenerative diseases. By reducing operational costs and testing times, the technology enables efficient first-line eye health screening for opticians and healthcare professionals.

```xml <problem> Current screening methods for visual and neurodegenerative diseases are often time-consuming, invasive, or unreliable, placing a strain on healthcare systems and delaying early detection. This is especially problematic given the increasing prevalence of conditions like glaucoma, Parkinson’s, and multiple sclerosis in an aging population. </problem> <solution> Reyedar offers a solution by combining eye-tracking technology and deep learning to collect biomarkers related to visual and neurological health. Their system uses AI-powered infrared eye-tracking glasses to measure eye movements in response to visual stimuli. The collected data is then analyzed using patented algorithms based on signal processing and deep neural networks, translating complex eye-tracking data into understandable clinical information. This approach enables fast, objective, and user-friendly screening for visual field sensitivity and qualitative risk indication for neurovisual disorders, providing a unique window into a patient's health. The functional vision test, called SONDA (Standardized Oculomotor Neuro-ophthalmic Disorders Assessment), is automatized, non-invasive, and can be completed in under 5 minutes. </solution> <features> - AI-powered infrared eye-tracking glasses for measuring eye movements - Patented algorithms based on signal processing and deep neural networks for data analysis - SONDA (Standardized Oculomotor Neuro-ophthalmic Disorders Assessment) functional vision test - Automatic calibration and virtual chinrest for ease of use - Integration with open-access software libraries for experimental design - Cloud software platform for wireless and remote operation - Easy-to-interpret reports with visual field sensitivity screening and risk indication - Collection of eye movement data without button pressing or complex instructions </features> <target_audience> Reyedar's primary customers include opticians, optometrists, hospitals, private clinics, and clinical research centers seeking efficient and reliable tools for early detection and screening of eye diseases and neurodegenerative disorders. </target_audience> ```

What does Reyedar do?

The startup manufactures medical devices that utilize eye tracking and artificial intelligence to expedite the diagnostic process for glaucoma and neurodegenerative diseases. By reducing operational costs and testing times, the technology enables efficient first-line eye health screening for opticians and healthcare professionals.

Where is Reyedar located?

Reyedar is based in Groningen, The Netherlands.

When was Reyedar founded?

Reyedar was founded in 2020.

How much funding has Reyedar raised?

Reyedar has raised 3420000.

Location
Groningen, The Netherlands
Founded
2020
Funding
3420000
Employees
9 employees
Major Investors
Cottonwood Technology Fund

Find Investable Startups and Competitors

Search thousands of startups using natural language

Reyedar

⚠️ AI-generated overview based on web search data – may contain errors, please verify information yourself! You can claim this account with your email domain to make edits.

Executive Summary

The startup manufactures medical devices that utilize eye tracking and artificial intelligence to expedite the diagnostic process for glaucoma and neurodegenerative diseases. By reducing operational costs and testing times, the technology enables efficient first-line eye health screening for opticians and healthcare professionals.

reyedar.com2K+
cb
Crunchbase
Founded 2020Groningen, The Netherlands

Funding

$

Estimated Funding

$3M+

Major Investors

Cottonwood Technology Fund

Team (5+)

No team information available.

Company Description

Problem

Current screening methods for visual and neurodegenerative diseases are often time-consuming, invasive, or unreliable, placing a strain on healthcare systems and delaying early detection. This is especially problematic given the increasing prevalence of conditions like glaucoma, Parkinson’s, and multiple sclerosis in an aging population.

Solution

Reyedar offers a solution by combining eye-tracking technology and deep learning to collect biomarkers related to visual and neurological health. Their system uses AI-powered infrared eye-tracking glasses to measure eye movements in response to visual stimuli. The collected data is then analyzed using patented algorithms based on signal processing and deep neural networks, translating complex eye-tracking data into understandable clinical information. This approach enables fast, objective, and user-friendly screening for visual field sensitivity and qualitative risk indication for neurovisual disorders, providing a unique window into a patient's health. The functional vision test, called SONDA (Standardized Oculomotor Neuro-ophthalmic Disorders Assessment), is automatized, non-invasive, and can be completed in under 5 minutes.

Features

AI-powered infrared eye-tracking glasses for measuring eye movements

Patented algorithms based on signal processing and deep neural networks for data analysis

SONDA (Standardized Oculomotor Neuro-ophthalmic Disorders Assessment) functional vision test

Automatic calibration and virtual chinrest for ease of use

Integration with open-access software libraries for experimental design

Cloud software platform for wireless and remote operation

Easy-to-interpret reports with visual field sensitivity screening and risk indication

Collection of eye movement data without button pressing or complex instructions

Target Audience

Reyedar's primary customers include opticians, optometrists, hospitals, private clinics, and clinical research centers seeking efficient and reliable tools for early detection and screening of eye diseases and neurodegenerative disorders.

Want to add first party data to your startup here or get your entry removed? You can edit it yourself by logging in with your company domain.